News & Events

Xyzagen’s Christopher Crean Presented Long-Acting Anti-VEGF Research at ARVO 2025 in Salt Lake City Pittsboro, NC – May 8, 2025 – Xyzagen, Inc., a leading pharmacokinetics

Xyzagen, Inc. Highlights Breakthrough Kv7 Channel Opener Chemistry at AES 2024 Pittsboro, NC, December 15, 2024 – Xyzagen, Inc., a leading pharmacokinetics consultancy and boutique

Novel Prodrug Approaches Show Promise in Neuropathic Pain, Epilepsy Treatment and Functional Neurological Seizures CHICAGO, IL, October 10, 2024 — Xyzagen, Inc., a pharmacokinetics consultancy

Xyzagen Expands Team with Strategic Hires, Enhancing Quantitative Medicine and Genomics Capabilities Pittsboro, NC – March 30, 2024 – Xyzagen, Inc., a leading pharmacokinetics consultancy

Xyzagen Expands Services, Provides Drug Stability Capabilities Pittsboro, NC – February 20, 2024 – Xyzagen, Inc., a leading pharmacokinetics consultancy and contract research organization (CRO),

Xyzagen Expands Team with Strategic Hires, Enhancing Quantitative Medicine and Genomics Capabilities Pittsboro, NC – January 1, 2024 – Xyzagen, Inc., a leading pharmacokinetics consultancy

Xyzagen Expands Laboratory in Pittsboro and Expands Services into In Vitro ADME Assays Pittsboro, NC – October 1, 2023 – Xyzagen, Inc., a leading pharmacokinetics

Xyzagen’s Founder, Christopher Crean, Presented Research on Kv7 Prodrugs at Kv7 Symposium Pittsboro, NC – September 16, 2023 – Xyzagen, Inc., a leading pharmacokinetics consultancy

Xyzagen Plays Critical Role in the Successful NDA Approval of XDEMVY Pittsboro, NC – July 27, 2023 – Xyzagen, a leading provider of drug development

Xyzagen Expands Expertise with New Team Members and Peptide LC-MS Capabilities Pittsboro, NC – July 13th, 2023 – Xyzagen, Inc., a pharmacokinetics consultancy and boutique

Xyzagen Presents Research on CPL-01 at ASPET 2023 Pittsboro, NC, May 12, 2023 – Xyzagen, Inc., a pharmacokinetics consultancy and boutique CRO, in support of

Xyzagen Presents Spring Discovery’s Research on Disulfiram at ARVO 2023 Pittsboro, NC, April 28, 2023 – Xyzagen, Inc., a pharmacokinetics consultancy and boutique CRO, unveiled

Xyzagen, Inc. Presented Promising Kv7 Channel Opener Prodrug Research at American Epilepsy Society Annual Meeting Novel Prodrug Approaches Demonstrate Effective Seizure Control Through Multiple Administration